Patent · US Expired

Selective apoptosis of neoplastic cells by an HLA-DR specific monoclonal antibody

US6416958B2 · kind B2 · utility

44Cited by
0References
5Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 13, 2001
Grant dateJul 9, 2002
Priority date—
Expiry dateAug 13, 2021

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/56
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Anti-human major histocompatibility complex (MHC) class II, HLA-DR-specific monoclonal antibodies which can induce apoptosis of HLA-DR positive cells are disclosed. The antibodies are used to specifically eliminate HLA-DR antigen positive tumor cells by cross-linking of HLA-DR. Also disclosed are methods for treating cancer using such antibodies, and compositions containing them.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.